Rani-Logo.jpg
Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update
March 22, 2023 16:05 ET | Rani Therapeutics, LLC
- Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis - -...
22157.jpg
Adalimumab Global Market Report 2022: Rising Prevalence of Arthritis and Clinical Trials to Spur Growth
February 22, 2023 09:33 ET | Research and Markets
Dublin, Feb. 22, 2023 (GLOBE NEWSWIRE) -- The "Adalimumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028: Segmented By Type (Biologics v/s Biosimilars), By...
Chinese Anti-Rheumatic Drug Market
China Anti-Rheumatic Drug Market Forecasts Report 2022-2027 - Growing Prevalence of Rheumatic Patients Leading to Increased Demand
January 20, 2023 06:58 ET | Research and Markets
Dublin, Jan. 20, 2023 (GLOBE NEWSWIRE) -- The "China Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.China Antirheumatic Drugs...
Global Adalimumab, Infliximab And Etanercept Biosimilars Market
Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2023: Increasing Healthcare Access Bolsters Sector
January 11, 2023 04:48 ET | Research and Markets
Dublin, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to ...
SAMSUNG BIOEPIS_2.jpg
Samsung Bioepis Presents Three-year Follow-up Data of Adalimumab Biosimilar SB5 in Patients with Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
September 07, 2022 02:01 ET | Samsung Bioepis
Long term follow-up data from British Association of Dermatologics and Immunomodulators Register (BADBIR) shows safety and effectiveness of SB5 in patients with psoriasis who have started or...
SAMSUNG BIOEPIS_2.jpg
Samsung Bioepis Announces New Data on Adalimumab Biosimilar, SB5 at the Annual European Congress of Rheumatology (EULAR 2022)
May 31, 2022 18:05 ET | Samsung Bioepis
Samsung Bioepis and Biogen to present one abstract and one poster at EULAR 2022 on adalimumab biosimilar, SB5 including Phase 1 study of a new SB5 formulation and a pan-European real-world study,...
Coherus BioSciences, Inc. logo
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
March 29, 2022 09:15 ET | Coherus BioSciences, Inc.
— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth – — Introducing 2026 revenue target of $1.2...
Coherus BioSciences, Inc. logo
Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
March 15, 2022 08:00 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Rosh Dias, MD, MRCP, has been appointed Chief Medical...
Coherus BioSciences, Inc. logo
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
December 20, 2021 07:59 ET | Coherus BioSciences, Inc.
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE...
22157.jpg
HUMIRA (Adalimumab) Biosimilars Market Report 2021: Current Developer Landscape and Clinical Research Scenario Related to All the Follow-on Products of the Blockbuster Biologic Drug
July 30, 2021 06:03 ET | Research and Markets
Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The "HUMIRA? (Adalimumab) Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars,...